News - Regeneron, Markets & Marketing

Filter

Popular Filters

New products will grow atopic dermatitis market to $5.6 billion by 2022

New products will grow atopic dermatitis market to $5.6 billion by 2022

15-11-2013

Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion…

Anacor PharmaceuticalsChinaDermatologicalsdupilumabEuropeIndiaMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads

11-07-2013

The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Oncologists favor Avastin as first-line therapy for metastatic colorectal cancer

27-06-2013

For the treatment of metastatic colorectal cancer (mCRC), a majority of surveyed US oncologists surveyed…

AvastinBayerBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck SeronoNorth AmericaOncologyPharmaceuticalRegeneronRocheSanofiStivargaZaltrap

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers

07-01-2013

After one year on the market, 86% of US retinal specialists have prescribed Regeneron's (Nasdaq: REGN)…

BayerBiotechnologyEyleaMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneron

Eye disorders drug sales set to reach $23.8 billion in 2016, predicts Visiongain

18-10-2012

Total worldwide revenues from drugs to treat eye disorders will reach $23.8 billion in 2016, according…

EyleaGlobalMarkets & MarketingOphthalmicsPharmaceuticalRegeneron

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report

24-07-2012

After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Santen to co-promote Bayer and Regeneron's Eylea in Japan

09-05-2012

German drug major Bayer's (BAYN: DE) Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical (TYO:…

Asia-PacificBayerEyleaLicensingMarkets & MarketingOphthalmicsPharmaceuticalRegeneronSanten Pharmaceuticals

Regeneron and Bayer’s Eylea backed by thought leaders for DME

13-02-2012

Based on clinical data and the opinions of interviewed thought leaders by health care advisory firm Decision…

AllerganBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsOzurdexPharmaceuticalRegeneron

Back to top